Cost-effectiveness of infant and maternal RSV immunization strategies, in British Columbia, Canada
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.New RSV prevention strategies, including nirsevimab and maternal RSVpreF vaccination, are more cost-effective than palivizumab for infants. Nirsevimab for high- and moderate-risk infants is the most cost-effective approach.
Area Of Science
- Pediatric Infectious Diseases
- Health Economics
- Public Health Policy
Background
- Respiratory syncytial virus (RSV) significantly impacts young children, causing substantial healthcare costs.
- Palivizumab was the historical standard for RSV prevention in high-risk infants.
- Newer options like nirsevimab and maternal RSVpreF vaccination are now available.
Purpose Of The Study
- To evaluate the cost-effectiveness of novel RSV prevention strategies compared to the historical standard of care.
- To model the impact of nirsevimab and maternal RSVpreF vaccination on healthcare outcomes and costs.
- To inform public health policy regarding RSV prevention in infants.
Main Methods
- A discrete-event simulation model was developed using data from British Columbia, Canada.
- Five immunization strategies were compared from a healthcare system perspective.
- Sequential and pairwise cost-effectiveness analyses were conducted, including ICER calculations.
Main Results
- Nirsevimab for high- and moderate-risk infants (strategy 2) was the most cost-effective option in sequential analysis.
- Maternal RSVpreF vaccination combined with nirsevimab for high- and moderate-risk infants (strategy 4) was cost-effective compared to the historical standard ($18,000/QALY).
- Strategy 4 offered additional health gains but was not incrementally cost-effective versus strategy 2 ($119,000/QALY).
Conclusions
- Prioritizing nirsevimab for high- and moderate-risk infants is recommended as the most cost-effective strategy.
- Maternal RSVpreF vaccination provides added health benefits and is cost-effective when compared to the historical standard of care.
- Nirsevimab and RSVpreF vaccination represent significant advancements in RSV prevention for young children.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
